-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The biology of acute myeloid leukemia (AML) changes with age; Older adults have a higher incidence of low-risk cytogenetics, including partial or complete loss of chromosomes 5 or 7 and the presence of
The study assessed the efficacy and safety
The researchers analyzed data
127 patients at low cytogenetic risk were treated with vinetok + azacitidine (TP53 wild-type 53, TP53-mutant 54-bit) compared
For patients at low cytogenetic risk of TP53 mutation, vinetok + azacitidine monotherapy improved the compound response rate (41% vs 17%), with median DoR of 6.
Patients with grade 3 and above of TP53 mutations in the Venetok + Azacitine and Azacitine single-agent groups had febrile neutropenia (55% vs 39%), thrombocytopenia (28% vs 28%), neutropenia (26% vs 17%), anemia (13% vs.
In summary, compared with azacitine alone, Vinetok plus azacitine increased the compound remission rate in patients with AML with a low cytogenetic risk of TP53 mutation, but did not prolong the duration of remission and overall survival
Original Source:
Daniel A.
